PH26787A - Use of omeprazole as an antimicrobial agent - Google Patents

Use of omeprazole as an antimicrobial agent Download PDF

Info

Publication number: PH26787A
Authority: PH; Philippines
Prior art keywords: omeprazole; salt; methoxy; antimicrobial agent; pharmaceutically acceptable
Prior art date: 1989-02-09

Application number

PH40033A

Other languages

English (en)

Inventor

Masaaki Tomoi

Yoshiko Yokota

Yoshifumi Ikeda

Original Assignee

Haessle Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-09

Filing date

1990-02-09

Publication date

1992-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH26787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-02-09 Application filed by Haessle Ab filed Critical Haessle Ab

1992-10-13 Publication of PH26787A publication Critical patent/PH26787A/en

Links

SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims description 19
229960000381 omeprazole Drugs 0.000 title description 17
239000004599 antimicrobial Substances 0.000 title description 10
150000003839 salts Chemical class 0.000 claims description 16
208000035473 Communicable disease Diseases 0.000 claims description 4
241000590002 Helicobacter pylori Species 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 2
206010051226 Campylobacter infection Diseases 0.000 claims 1
239000004480 active ingredient Substances 0.000 description 13
239000002775 capsule Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000000203 mixture Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
-1 alkali metal salts Chemical class 0.000 description 6
239000004615 ingredient Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
230000000845 anti-microbial effect Effects 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000007787 solid Substances 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
241000589562 Brucella Species 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
229940063517 omeprazole sodium Drugs 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000589876 Campylobacter Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
241000009328 Perro Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
CDZHZLQKNAKKEC-UHFFFAOYSA-N [bis(hydroxymethylamino)methylamino]methanol Chemical class OCNC(NCO)NCO CDZHZLQKNAKKEC-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000003912 environmental pollution Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002597 lactoses Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical class C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
238000011160 research Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PH40033A 1989-02-09 1990-02-09 Use of omeprazole as an antimicrobial agent PH26787A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP1030311A JP2694361B2 (ja)	1989-02-09	1989-02-09	抗菌剤

Publications (1)

Publication Number	Publication Date
PH26787A true PH26787A (en)	1992-10-13

Family

ID=12300238

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH40033A PH26787A (en)	1989-02-09	1990-02-09	Use of omeprazole as an antimicrobial agent

Country Status (19)

Country	Link
US (1)	US5093342A (de)
EP (1)	EP0414847B1 (de)
JP (1)	JP2694361B2 (de)
KR (1)	KR0140236B1 (de)
AT (1)	ATE94063T1 (de)
AU (1)	AU626641B2 (de)
CA (1)	CA2025668C (de)
CY (1)	CY1909A (de)
DE (1)	DE69003207T2 (de)
DK (1)	DK0414847T3 (de)
ES (1)	ES2058892T3 (de)
HK (1)	HK52196A (de)
HU (1)	HU205253B (de)
IE (1)	IE65814B1 (de)
IL (1)	IL93263A0 (de)
LV (1)	LV10577B (de)
MY (1)	MY111737A (de)
PH (1)	PH26787A (de)
WO (1)	WO1990009175A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2066120T3 (es) *	1989-02-10	1995-03-01	Takeda Chemical Industries Ltd	Uso de derivados de bencimidazol como agentes antibacterianos.
GB9018603D0 (en) *	1990-08-24	1990-10-10	Smith Kline French Lab	Compositions
ES2169022T3 (es) *	1990-09-14	2002-07-01	Byk Gulden Lomberg Chem Fab	Utilizacion de derivados de (piridil-metil-sulfinil)-1-h-bencimidazol para el tratamiento de enfermedades provocadas por helicobacter.
IS3990A (is) *	1992-04-24	1993-10-25	Ab Astra	Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi
US5504082A (en) *	1992-06-01	1996-04-02	Yoshitomi Pharmaceutical Industries, Ltd.	Pyridine compound and pharmaceutical compostions
EP0673246A1 (de) *	1992-12-10	1995-09-27	Byk Gulden Lomberg Chemische Fabrik GmbH	Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
US6426085B1 (en)	1994-05-02	2002-07-30	Josman Laboratories Inc.	Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) *	1994-05-02	1998-11-10	Josman Laboratories, Inc.	Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) *	1994-05-02	2005-06-07	Josman Laboratories, Inc.	Topical oral dosage forms containing bismuth compounds
AU5019196A (en) *	1995-02-07	1996-08-27	Narayan Krishnarao Athanikar	Concomitant treatment with oral bismuth compounds
US6379651B1 (en)	1995-02-07	2002-04-30	Josman Laboratories	Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en)	1995-02-07	2002-04-16	Josman Laboratories, Inc.	Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US5708017A (en) *	1995-04-04	1998-01-13	Merck & Co., Inc.	Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6699885B2 (en)	1996-01-04	2004-03-02	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) *	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
US6645988B2 (en)	1996-01-04	2003-11-11	Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
SI9700186B (sl)	1997-07-14	2006-10-31	Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.	Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6096340A (en) *	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6174548B1 (en)	1998-08-28	2001-01-16	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
DK1037607T3 (da) *	1997-12-08	2004-06-21	Altana Pharma Ag	Hidtil ukendt suppositoriumsform, der omfatter en syrelabil aktiv forbindelse
US6861448B2 (en) *	1998-01-14	2005-03-01	Virtual Drug Development, Inc.	NAD synthetase inhibitors and uses thereof
CA2317439A1 (en)	1998-01-14	1999-07-22	Wayne J. Brouillette	Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6733778B1 (en) *	1999-08-27	2004-05-11	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6245913B1 (en)	1999-06-30	2001-06-12	Wockhardt Europe Limited	Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262086B1 (en)	1999-08-26	2001-07-17	Robert R. Whittle	Pharmaceutical unit dosage form
US6326384B1 (en)	1999-08-26	2001-12-04	Robert R. Whittle	Dry blend pharmaceutical unit dosage form
US6312723B1 (en)	1999-08-26	2001-11-06	Robert R. Whittle	Pharmaceutical unit dosage form
US6780880B1 (en)	1999-08-26	2004-08-24	Robert R. Whittle	FT-Raman spectroscopic measurement
US6369087B1 (en) *	1999-08-26	2002-04-09	Robert R. Whittle	Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en)	1999-08-26	2001-07-17	Robert R. Whittle	Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en)	1999-08-26	2001-11-06	Robert R. Whittle	Method of improving bioavailability
US6268385B1 (en)	1999-08-26	2001-07-31	Robert R. Whittle	Dry blend pharmaceutical formulations
US6316020B1 (en)	1999-08-26	2001-11-13	Robert R. Whittle	Pharmaceutical formulations
US6787342B2 (en)	2000-02-16	2004-09-07	Merial Limited	Paste formulations
SE0002476D0 (sv)	2000-06-30	2000-06-30	Astrazeneca Ab	New compounds
EP2147679B1 (de)	2001-07-25	2014-06-25	Raptor Pharmaceutical, Inc.	Zusammensetzungen für den Blut-Hirn-Schrankentransport
MXPA04007169A (es) *	2002-01-25	2004-10-29	Santarus Inc	Suministro transmucosal de inhibidores de bomba de protones.
JP2006518751A (ja) *	2003-02-20	2006-08-17	サンタラスインコーポレイティッド	胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US8993599B2 (en) *	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI398273B (zh) *	2003-07-18	2013-06-11	Santarus Inc	用於抑制酸分泌之醫藥調配物及其製備及使用之方法
MXPA06000524A (es) *	2003-07-18	2006-08-11	Santarus Inc	Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
US20070292498A1 (en) *	2003-11-05	2007-12-20	Warren Hall	Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8815916B2 (en) *	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP2392258B1 (de)	2005-04-28	2014-10-08	Proteus Digital Health, Inc.	Pharma-Informatiksystem
ATE533757T1 (de)	2006-03-10	2011-12-15	Arigen Pharmaceuticals Inc	Neues pyridinderivat mit wirkung gegen helicobacter pylori
CN101594878A (zh)	2006-09-18	2009-12-02	雷普特药品公司	通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
US20090092658A1 (en) *	2007-10-05	2009-04-09	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008067037A2 (en)	2006-10-05	2008-06-05	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en)	2006-10-27	2008-05-15	The Curators Of The University Of Missouri	Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
MX2009006638A (es)	2006-12-18	2009-07-02	Arigen Pharmaceuticals Inc	Agente para erradicar helicobacter pylori que tiene actividad inhibidora sobre la secrecion de acido gastrico.
PL3395372T3 (pl)	2009-02-20	2022-07-25	EnhanX Biopharm Inc.	Układ do dostarczania leków na bazie glutationu
JP5543432B2 (ja)	2009-04-09	2014-07-09	リンク・ジェノミクス株式会社	ピリジンチオ誘導体及びそれを含有する抗ヘリコバクター・ピロリ作用を有する医薬組成物
CN102458374A (zh)	2009-05-06	2012-05-16	实验室护肤股份有限公司	包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其使用方法
US8722026B2 (en) *	2010-01-06	2014-05-13	Elc Management, Llc	Skin lightening compositions
US8992897B2 (en)	2010-01-06	2015-03-31	Elc Management Llc	Skin lightening compositions
US20120077778A1 (en)	2010-09-29	2012-03-29	Andrea Bourdelais	Ladder-Frame Polyether Conjugates
KR101628474B1 (ko) *	2014-08-27	2016-06-08	경북대학교 산학협력단	오메프라졸을 유효성분으로 포함하는 피부 미백용 화장료 조성물
EP4598528A1 (de)	2022-10-04	2025-08-13	Arsenil Zabirnyk	Hemmung der verkalkung der aortenklappe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
US4359465A (en) *	1980-07-28	1982-11-16	The Upjohn Company	Methods for treating gastrointestinal inflammation
SE8301182D0 (sv) *	1983-03-04	1983-03-04	Haessle Ab	Novel compounds
EP0338066A1 (de) *	1987-10-30	1989-10-25	Aktiebolaget Hässle	2-pyridinylmethyl(sulfinyl oder thio)benzimidazole zur behandlung von krankheiten bezüglich beinverlusts

1989
- 1989-02-09 JP JP1030311A patent/JP2694361B2/ja not_active Expired - Lifetime
1990
- 1990-02-02 AU AU50381/90A patent/AU626641B2/en not_active Ceased
- 1990-02-02 KR KR1019900702221A patent/KR0140236B1/ko not_active Expired - Fee Related
- 1990-02-02 CY CY190990A patent/CY1909A/xx unknown
- 1990-02-02 DE DE90902854T patent/DE69003207T2/de not_active Expired - Fee Related
- 1990-02-02 IL IL93263A patent/IL93263A0/xx not_active IP Right Cessation
- 1990-02-02 HU HU901539A patent/HU205253B/hu not_active IP Right Cessation
- 1990-02-02 US US07/572,951 patent/US5093342A/en not_active Expired - Fee Related
- 1990-02-02 EP EP90902854A patent/EP0414847B1/de not_active Expired - Lifetime
- 1990-02-02 CA CA002025668A patent/CA2025668C/en not_active Expired - Lifetime
- 1990-02-02 DK DK90902854.0T patent/DK0414847T3/da active
- 1990-02-02 AT AT90902854T patent/ATE94063T1/de not_active IP Right Cessation
- 1990-02-02 ES ES90902854T patent/ES2058892T3/es not_active Expired - Lifetime
- 1990-02-02 WO PCT/SE1990/000070 patent/WO1990009175A1/en not_active Ceased
- 1990-02-06 IE IE41890A patent/IE65814B1/en not_active IP Right Cessation
- 1990-02-09 PH PH40033A patent/PH26787A/en unknown
- 1990-02-09 MY MYPI90000213A patent/MY111737A/en unknown
1994
- 1994-08-30 LV LVP-94-169A patent/LV10577B/en unknown
1996
- 1996-03-21 HK HK52196A patent/HK52196A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU5038190A (en)	1990-09-05
ATE94063T1 (de)	1993-09-15
CY1909A (en)	1990-02-02
LV10577A (lv)	1995-04-20
AU626641B2 (en)	1992-08-06
EP0414847B1 (de)	1993-09-08
WO1990009175A1 (en)	1990-08-23
HU901539D0 (en)	1991-02-28
EP0414847A1 (de)	1991-03-06
HU205253B (en)	1992-04-28
DE69003207T2 (de)	1994-02-03
IL93263A0 (en)	1990-11-29
KR910700048A (ko)	1991-03-13
DK0414847T3 (da)	1993-12-13
DE69003207D1 (de)	1993-10-14
US5093342A (en)	1992-03-03
MY111737A (en)	2000-12-30
KR0140236B1 (ko)	1998-06-01
JPH02209809A (ja)	1990-08-21
CA2025668C (en)	1998-09-15
HK52196A (en)	1996-03-29
JP2694361B2 (ja)	1997-12-24
IE900418L (en)	1990-08-09
CA2025668A1 (en)	1990-08-10
IE65814B1 (en)	1995-11-15
ES2058892T3 (es)	1994-11-01
HUT54890A (en)	1991-04-29
LV10577B (en)	1995-10-20

Publication	Publication Date	Title
AU626641B2 (en)	1992-08-06	Use of omeprazole as an antimicrobial agent
EP0382489B1 (de)	1994-11-17	Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel
DE69424487T2 (de)	2001-01-18	Formulierung enthaltend einen antibakteriellen und einen Antiulcus Wirkstoff
CA1302891C (en)	1992-06-09	Pharmaceutical formulations of acid labile substances for oral use
US4451457A (en)	1984-05-29	Cyclodextrin and method for promoting the proliferation of intestinal bifidobacteria
JP3593357B2 (ja)	2004-11-24	抗菌剤
US6426369B1 (en)	2002-07-30	Oxethazaine as antimicrobial agent
US5576341A (en)	1996-11-19	2-[[2-(N-isobutyl-N-methyl)amino]benzylsulfinyl]-benzimidazole as antimicrobial agent
PT655249E (pt)	2001-08-30	Moenomicina como medicamento para o tratamento de ulceras gastricas
JPH06500547A (ja)	1994-01-20	ピリジルメチルスルフィニル―１ｈ―ベンゾイミダゾール誘導体のヘリコバクターにより起こされる病気の治療のための使用
AU665043B2 (en)	1995-12-14	Substituted benzimidazoles, process for their preparation as well as their use
US6017950A (en)	2000-01-25	Methods for controlling gram negative bacteria in mammals
US6362169B1 (en)	2002-03-26	Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
JPS6234038B2 (de)	1987-07-24
WO1999052530A1 (fr)	1999-10-21	Agents antibacteriens
JPH0296527A (ja)	1990-04-09	抗潰瘍剤
JPH03161440A (ja)	1991-07-11	抗菌剤
JPH0977766A (ja)	1997-03-25	４−アミノ−５−ピリミジンカルボン酸誘導体を有効成分とする抗菌剤
JPH08169827A (ja)	1996-07-02	抗ウレアプラズマ属菌剤
JPH08337529A (ja)	1996-12-24	上部消化管疾患治療剤
JPH0725767A (ja)	1995-01-27	ウレアーゼ阻害剤
JP2001518093A (ja)	2001-10-09	細胞壁の生合成を阻害するウンデカプレノール・キナーゼ阻害剤の使用
JPH09295938A (ja)	1997-11-18	消化性潰瘍治療剤
JPWO1999043327A1 (ja)	2002-10-08	相乗作用のある抗菌剤組成物、それを含有する医薬および消化器疾患治療剤、それらの製造法、ならびにそれに関連する製剤